<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03582449</url>
  </required_header>
  <id_info>
    <org_study_id>SHP ELA-701</org_study_id>
    <nct_id>NCT03582449</nct_id>
  </id_info>
  <brief_title>Intensive Pharmacovigilance Program for Elaprase (SHP ELA-701)</brief_title>
  <official_title>Intensive Pharmacovigilance Program for Elaprase (SHP ELA-701)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shire</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shire</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this non-interventional, observational study which is conducted in Mexico is
      to evaluate the safety profile of elaprase (idulsurfase) in participants with hunter syndrome
      (mucopolysaccharydosis II) being treated with elaprase.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 19, 2018</start_date>
  <completion_date type="Anticipated">November 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Adverse Events During Administration of Elaprase</measure>
    <time_frame>During 12 months of study participation</time_frame>
    <description>An adverse event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered as a pharmaceutical product that do not necessarily have a causal relationship with this treatment. Incidence of adverse events during administration of elaprase will be reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Adverse Events According to the System Organ Class and MedDRA Preferred Term</measure>
    <time_frame>During 12 months of study participation</time_frame>
    <description>An AE is defined as any untoward medical occurrence in a clinical investigation participant administered as a pharmaceutical product that do not necessarily have a causal relationship with this treatment. Incidence of adverse events according to the system organ class and MedDRA preferred term will be reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Adverse Events 2 months After Early Termination of Elaprase Treatment.</measure>
    <time_frame>2 months after early termination of Elaprase treatment</time_frame>
    <description>An AE is defined as any untoward medical occurrence in a clinical investigation participant administered as a pharmaceutical product that do not necessarily have a causal relationship with this treatment. Incidence of adverse events 2 months after early termination of Elaprase treatment will be reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Height Over One Year Study Period</measure>
    <time_frame>Baseline, 12 months</time_frame>
    <description>Change in height over one year study period will be assessed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Weight Over One Year Study Period</measure>
    <time_frame>Baseline, 12 months</time_frame>
    <description>Change in weight over one year study period will be assessed.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Hunter Syndrome</condition>
  <arm_group>
    <arm_group_label>Elaprase</arm_group_label>
    <description>Participants with Hunter syndrome (Mucopolysaccharydosis II) being treated with Elaprase will be evaluated for this study.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Participants with hunter syndrome (mucopolysaccharydosis II) being treated with elaprase
        will be evaluated for this study.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participants of both genders

          -  Participants to whom idursulfase (Elaprase) has been prescribed

          -  Participants with Hunter syndrome

          -  Participants accepting to participate

          -  Participants signing the informed consent and privacy notice for handling personal
             information in: the program Contigo Shire (training, diagnosis, family trees) and the
             intensive pharmacovigilance study for Elaprase. If the participant is unable to
             provide legal consent (example: under legal age), the participant's legal guardian
             must provide consent

        Exclusion Criteria:

          -  Participants withdrawing their consent to continue participating in the
             non-intervention intensive pharmacovigilance study for Elaprase

          -  Known hypersensitivity or presence of any contraindication to Elaprase that cannot be
             controlled by pre-medication

          -  A physical condition that would not permit intravenous administration of enzyme
             replacement therapy (ERT)

          -  Participants enrolled in Shire sponsored Elaprase Registry or any other Shire
             sponsored Elaprase study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shire Study Physician</last_name>
    <role>Study Director</role>
    <affiliation>Shire</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shire Contact</last_name>
    <phone>+1 866 842 5335</phone>
    <email>ClinicalTransparency@shire.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital Pediátrico de Sinaloa</name>
      <address>
        <city>Culiacán Rosales</city>
        <state>México</state>
        <zip>80200</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Lyali Margarita Corrales, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IMSS UMAE 25 (INSTITUTO MEXICANO DEL SEGURO SOCIAL UNIDAD MEDICA DE ALTA ESPECIALIDAD No 25)</name>
      <address>
        <city>Monterrey</city>
        <state>Nuevo León</state>
        <zip>64180</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Luz Maria Sanchez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital del Niño Tabasqueño</name>
      <address>
        <city>Villahermosa</city>
        <state>Tabasco</state>
        <zip>86100</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Eduardo Gorian, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Centenario Miguel Hidalgo</name>
      <address>
        <city>Aguascalientes</city>
        <zip>CP 20000</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jaime López Valdez, MD</last_name>
      <phone>52 449 9946720</phone>
    </contact>
    <investigator>
      <last_name>Jaime López Valdez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Infantil Federico Gomez</name>
      <address>
        <city>Ciudad de México</city>
        <zip>06720</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Magdalena Cerón Rodriguez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Colima</name>
      <address>
        <city>Colima</city>
        <zip>28019</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Araceli Zamora, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>June 28, 2018</study_first_submitted>
  <study_first_submitted_qc>June 28, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 11, 2018</study_first_posted>
  <last_update_submitted>May 7, 2019</last_update_submitted>
  <last_update_submitted_qc>May 7, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 9, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hunter syndrome (Mucopolysaccharydosis II)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mucopolysaccharidosis II</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Shire provides access to the de-identified individual participant data for eligible studies to aid qualified researchers in addressing legitimate scientific objectives. These IPDs will be provided following approval of a data sharing request, and under the terms of a data sharing agreement.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_access_criteria>IPD from eligible studies will be shared with qualified researchers according to the criteria and process described in the Data Sharing section of the www.shiretrials.com website. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.</ipd_access_criteria>
    <ipd_url>https://www.shiretrials.com/en/our-commitment-to-transparency/data-sharing-with-researchers</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

